Innovative HIV Treatment ImmunoScience specializes in a groundbreaking therapeutic vaccine for HIV and AIDS, with promising pre-clinical and pilot trial results, positioning it as a potential leader in HIV cure research and attracting significant global interest.

Global Expansion Potential The company is preparing for Phase I clinical trials across multiple countries including the United States, Belgium, Ghana, and Uganda, indicating opportunities for international partnerships and collaborations in clinical development and distribution.

Patent Portfolio With several patents secured worldwide for Contre Vir™, ImmunoScience has strong intellectual property assets that can be leveraged for licensing, joint ventures, or exclusive distribution agreements in the biotech sector.

Funding & Revenue Growth Although current revenues are between one and ten million dollars, potential for accelerated growth exists through strategic partnerships, given the high interest and advanced trial stages of its flagship product.

Technology Stack Utilizing industry-standard web technologies like DreamWeaver, jQuery, Apache, and Nginx, ImmunoScience maintains a robust online presence, providing opportunities for digital partnership, outreach, and targeted marketing efforts to engage stakeholders and investors.